Michael H Gold, MD

Tennessee Clinical Research Center
2000 Richard Jones Road
Nashville, TN
USA 37215
Papers:
Treatment of Moderate-to-Severe Glabellar Lines with Relabotulinumtoxina, a New Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the Ready-1 Phase III Trial